Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology - PubMed (original) (raw)
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology
N Sin et al. Bioorg Med Chem Lett. 1999.
Free article
Abstract
Epoxomicin (1), a peptide alpha',beta'-epoxyketone isolated from the actinomycete strain No.Q996-17, possesses potent in vivo anti-tumor and anti-inflammatory activities. In this paper, we report the first syntheses of epoxomicin, [3H]-epoxomicin, and a biotinylated epoxomicin analog as well as the absolute configuration of the epoxide stereocenter. The natural product and derivatives have permitted the first identification of the proteasome as the specific cellular target of epoxomicin.
Similar articles
- Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity.
Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM. Meng L, et al. Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10403-8. doi: 10.1073/pnas.96.18.10403. Proc Natl Acad Sci U S A. 1999. PMID: 10468620 Free PMC article. - Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency.
Kim KB, Myung J, Sin N, Crews CM. Kim KB, et al. Bioorg Med Chem Lett. 1999 Dec 6;9(23):3335-40. doi: 10.1016/s0960-894x(99)00612-5. Bioorg Med Chem Lett. 1999. PMID: 10612595 - Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha',beta'-epoxyketones.
Elofsson M, Splittgerber U, Myung J, Mohan R, Crews CM. Elofsson M, et al. Chem Biol. 1999 Nov;6(11):811-22. doi: 10.1016/s1074-5521(99)80128-8. Chem Biol. 1999. PMID: 10574782 - Proteasomes and proteasome inhibition in the central nervous system.
Ding Q, Keller JN. Ding Q, et al. Free Radic Biol Med. 2001 Sep 1;31(5):574-84. doi: 10.1016/s0891-5849(01)00635-9. Free Radic Biol Med. 2001. PMID: 11522442 Review. - Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy.
Dou QP, Smith DM, Daniel KG, Kazi A. Dou QP, et al. Prog Cell Cycle Res. 2003;5:441-6. Prog Cell Cycle Res. 2003. PMID: 14593738 Review.
Cited by
- The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses.
Schwarz K, de Giuli R, Schmidtke G, Kostka S, van den Broek M, Kim KB, Crews CM, Kraft R, Groettrup M. Schwarz K, et al. J Immunol. 2000 Jun 15;164(12):6147-57. doi: 10.4049/jimmunol.164.12.6147. J Immunol. 2000. PMID: 10843664 Free PMC article. - Niclosamide prevents the formation of large ubiquitin-containing aggregates caused by proteasome inhibition.
Gies E, Wilde I, Winget JM, Brack M, Rotblat B, Novoa CA, Balgi AD, Sorensen PH, Roberge M, Mayor T. Gies E, et al. PLoS One. 2010 Dec 23;5(12):e14410. doi: 10.1371/journal.pone.0014410. PLoS One. 2010. PMID: 21203451 Free PMC article. - Targeted protein destabilization reveals an estrogen-mediated ER stress response.
Raina K, Noblin DJ, Serebrenik YV, Adams A, Zhao C, Crews CM. Raina K, et al. Nat Chem Biol. 2014 Nov;10(11):957-62. doi: 10.1038/nchembio.1638. Epub 2014 Sep 21. Nat Chem Biol. 2014. PMID: 25242550 Free PMC article. - Solid-Phase Synthesis and Application of a Clickable Version of Epoxomicin for Proteasome Activity Analysis.
Salazar-Chaparro AF, Halder S, Maresh ME, Trader DJ. Salazar-Chaparro AF, et al. Chembiochem. 2022 Apr 5;23(7):e202100710. doi: 10.1002/cbic.202100710. Epub 2022 Feb 21. Chembiochem. 2022. PMID: 35107861 Free PMC article. - Inhibition of hepatitis B virus replication by interferon requires proteasome activity.
Robek MD, Wieland SF, Chisari FV. Robek MD, et al. J Virol. 2002 Apr;76(7):3570-4. doi: 10.1128/jvi.76.7.3570-3574.2002. J Virol. 2002. PMID: 11884582 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources